Report of Foreign Issuer (6-k)
July 28 2016 - 2:00PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 28 July 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc (the
'
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Sir Andrew Witty
|
b)
|
Position/status
|
CEO
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
Sale of Ordinary Shares on 27 July 2016 at a price of £16.9350.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.9350
|
10,000
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-27
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
The exercise of options over 26,800 Ordinary Shares, granted on 20 February 2007 under the GlaxoSmithKline Share Option Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£14.88
|
26,800
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-27
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
The sale of 26,800 Ordinary Shares following the exercise of options granted on 20 February 2007 under the GlaxoSmithKline Share Option Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.942
|
26,800
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-27
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
The exercise of options over 24,186 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£11.47
|
24,186
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-27
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
The sale of 24,186 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.938
|
24,186
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-27
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
The exercise of options over 2,614 Ordinary Shares, granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£11.47
|
2,614
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-28
|
f)
|
Place of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Mr D S Redfern
|
b)
|
Position/status
|
Chief Strategy Officer
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
The sale of 2,614 Ordinary Shares following the exercise of options granted on granted on 19 February 2008 under the GlaxoSmithKline Share Option Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.035
|
2,614
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-28
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them ('PCA')
|
a)
|
Name
|
Ms C Thomas
|
b)
|
Position/status
|
Senior Vice President, Human Resources
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
|
a)
|
Description
of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the transaction
|
Sale of Ordinary Shares on 28 July 2016 at a price of £16.9757.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£16.9757
|
43,000
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of the transaction
|
2016-07-28
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 28, 2016
By: VICTORIA WHYTE
----------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024